Science Exchange Announces Outsourced R&D Partnership with Alector

November 20, 2017 | Posted by Team in Company, Drug Discovery, Outsourcing Best Practices, Press Release, Science Exchange News |

Science Exchange-Alector PartnershipPALO ALTO, Calif.–Science Exchange, the world’s leading and most secure enterprise platform and aggregator for outsourced research and development (R&D), today announced a strategic partnership with Alector, a biotech company pioneering the discovery & development of immuno-neurology therapies for neurodegenerative disorders, to provide the company’s scientists access to a private R&D marketplace to accelerate their research.

“The Science Exchange platform solves the challenges of R&D outsourcing: we provide scientists with efficient access to a diverse network of qualified suppliers under a single relationship, and at the same time we provide sourcing departments with more information and control over their outsourcing spend,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be the provider of Alector’s R&D marketplace and help bring potential treatments for Alzheimer’s disease to patients more quickly and efficiently. Especially following the exciting news on Alector’s partnership with AbbVie to advance therapies for Alzheimer’s disease, it’s clear that Alector has extremely promising drug targets — we’re honored to help accelerate these important discoveries.”

The Science Exchange-powered R&D marketplace enables scientists to instantly order more than 6,000 unique scientific services from the 2,500 CROs, academic labs, and government facilities that are available under a single Science Exchange contract. The partnership also will provide Alector with a platform to effectively manage the company’s outsourced R&D investments, including the ability to track supplier utilization, trends, and performance, which also supports the need for compliance with internal policies and external regulations.

Alector is the latest R&D company to choose to partner with Science Exchange, and joins more than 30 enterprise organizations, including 10 of the top 20 pharma companies, that use Science Exchange to more efficiently manage outsourced R&D.

“Science Exchange offers a unique platform for connecting with a broad network of qualified scientific service providers,” said Arnon Rosenthal, Ph.D., co-founder and CEO of Alector. “It is our hope that working with Science Exchange will enable us to more quickly advance discovery and development of novel immuno-neurology therapies.”

Under the agreement, Science Exchange will support company-specific governance, approval workflows, and preferred vendors. To minimize the risk frequently associated with outsourcing to external service providers, the Science Exchange guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by a best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated work.

 

Visit www.scienceexchange.com/enterprise to request a demo of our award-winning private marketplaces for managing outsourced research and development!

Science Exchange Scientific Provider Elion Labs Presenting New Research at the AAPS Annual Meeting

November 13, 2017 | Posted by Team in Drug Discovery, Events, New Innovations, Press Release, Research |
  • Breakthrough in drug product particle analysis using machine learning

  • Biopharma researchers can access Elion’s new services from scienceexchange.com

Science Exchange and Elion at AAPS

PALO ALTO, CA, and LOUISVILLE, CO, November 13, 2017 Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development, is proud to announce that Elion Labs, provider of analytical development and drug product characterization services, will present exciting new research at the 2017 AAPS (American Association of Pharmaceutical Scientists) Annual Meeting, the most comprehensive event for innovations in bioanalysis, formulation, and product characterization.

Elion’s expertise has helped bring numerous clinical products to market. Their AAPS research poster presentation (Abstract M8003) introduces a novel method for drug product analysis, using machine learning and advanced image analysis to improve particle detection, enumeration, and classification.

“Machine learning approaches open up exciting new possibilities for analyzing particles in biologics, and ultimately, for better analyzing a broad range of complex data sets,”  said John Gabrielson, Ph.D., CEO and Founding Partner of Elion Labs. “We hope that our research will help biopharmaceutical researchers develop safer, more effective drugs and deliver them to patients faster.”

Elion and Science Exchange will exhibit at booth 2337 at AAPS, meeting drug discovery and development researchers and representatives of regulatory agencies seeking the latest, innovative services available for pharmaceutical analysis.

“We’re proud to participate in this year’s conference alongside Elion, who are true thought leaders in analytical research,” said Elizabeth Iorns, Ph.D., CEO and Co-Founder of Science Exchange. “And because they’re part of the Science Exchange network, biopharmaceutical researchers can access Elion’s technologies immediately under our pre-existing master service agreement that covers IP and confidentiality.”

More information about Elion Labs and their innovative services can be found at www.scienceexchange.com/labs/elion-labs.

 

About Elion Labs

Elion Labs, based in Louisville, Colorado, USA, was founded to serve the analytical development and product characterization needs of the biopharmaceutical industry. Elion offers a variety of services, including analytical method development, qualification and validation; analytical characterization testing of biologics; formulation development; training in highly specialized analytical techniques; comprehensive data analysis including visualization and interpretation of complex data sets; technical and regulatory writing; and technical consulting. They are committed to providing all services with unmatched professionalism, quality, and speed.

About Science Exchange

Science Exchange is the world’s leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.

 

 

New on Science Exchange: VR Tech, Cancer Genetics, Stem Cell-based Organoids

October 26, 2017 | Posted by Team in Drug Discovery, Helpful products, New Innovations, Research |

Chandreyee Das, Ph.D. | Senior Content Manager, Science Exchange | www.scienceexchange.com

Nanome Virtual Reality

Virtual Reality Software: Explore biology at nanoscale

From “Fantastic Voyage” (1966) to “A Wind in the Door” (1973), fiction has adored the idea of exploring the body at cellular and molecular levels. Now, virtual reality (VR) software, combined with the computational power afforded by blockchain technology, makes such journeys possible.

For your next computer-aided drug discovery/development (CADD) project, especially if you are collaborating with researchers across multiple sites, try molecular visualization using VR technology — now available from Nanome through Science Exchange.

Visit the Nanome storefront to connect with their team!

 

Cancer Genetics: Connect patients to discoveries

It’s a great day for precision medicine, with the unveiling of the first global directory of patient-derived xenografts (PDX).

Despite the attention given to precision medicine, however, less than 5% of cancer patients are participating in clinical trials. In the discovery phases of R&D, obtaining biospecimens of specific genotypes is also a continuing challenge.

Oncologists on Science Exchange can now accelerate their research with Cancer Genetics, Inc., a global CRO with a history of thought leadership in precision medicine.

Start a project today with Cancer Genetics, Inc.

 

Stem Cell-based 3D Organoids: Predict Preclinical Efficacy and Toxicity

3Dnamics Organoid Hippocampus

Organoids, particularly brain organoids, have enabled breakthrough research in Alzheimer’s disease, glioblastoma, and even ZIKA virus-induced microcephaly. By using pluripotent stem cells as a source of the multiple cell types present in an organoid, preclinical researchers can recapitulate in vivo-like tissue architecture and cellular heterogeneity.

Many of these discoveries were made by the founders of 3Dnamics, a new service provider on the Science Exchange network. The 3Dnamics team was built by stem cell pioneers and neuroscientists at Johns Hopkins University School of Medicine. If you are in the process of developing a model system for your preclinical or discovery-phase research, take advantage of 3Dnamics’ expertise.

Visit the 3Dnamics storefront

 

Accelerating Innovation and Mitigating Risk in Outsourced R&D

October 25, 2017 | Posted by Team in Drug Discovery, Events, Outsourcing Best Practices, Science Exchange News, Workshops |

Science Exchange Summit 2017

by Elizabeth Iorns, Ph.D., CEO and Co-Founder, Science Exchange | www.scienceexchange.com

Science Exchange recently hosted a group of procurement executives from multiple industries for our 2017 Science Exchange Outsourced R&D Leadership Summit. During the informative and interactive sessions, we discussed both the challenges and opportunities that organizations are facing as they seek to effectively manage outsourced R&D services.

From presentations by procurement leaders from major pharmaceutical companies on how they’re structuring procurement to enable innovation, to insights on how Science Exchange is pioneering new ways to make it easier to access innovation from our service providers, one of the key themes of the day was the potential for the procurement function to empower scientists to achieve breakthrough discovery. Here are some of my notes around the theme of innovation:

  • Procurement leaders can drive innovation, with the right tools. A pharmaceutical company procurement leader responsible for driving innovation shared that, in less than six months of working with Science Exchange, they had been able to increase their use of new, niche service providers by 11%.
  • Innovation can be hampered by complex processes. Natalie Foote, our Director of Service Provider Operations, presented with two of our service providers — iSpecimen and LabNetwork, a WuXi AppTec company– about new technology integrations with our platform. These integrations allow Science Exchange users to access the iSpecimen and LabNetwork marketplaces through a seamless access point on our platform — no barriers to innovation!
  • Flexible, agile procurement support helps drive innovation. During a panel discussion that I moderated, procurement leaders from three global pharmaceutical companies examined the need to more flexible and agile when it comes to managing R&D requests, and supporting the R&D business through an end-to-end process. They also discussed how their organizations must strategically examine the best mix of internal and external capabilities, core strengths and capacity when it comes to maximizing R&D innovation.

Another theme that surfaced during the Summit was risk mitigation, including the need to better manage confidentiality, data security and intellectual property (IP), and how to prepare for business continuity — whether caused by security breaches or natural disasters. My notes on the theme of risk mitigation:

  • Proactively mitigate risk. During the panel discussion, procurement leaders talked about the need to move beyond a “paper exercise” for managing risk, to a more proactive and rigorous approach to protecting their companies from data and security breaches and business continuity issues. One panelist discussed the drive for holding the business accountable for third-party risk oversight on a global scale, to move beyond that “check the box” mentality.   
  • Balance risk and innovation opportunity. Another panelist emphasized how important it is to strike the delicate balance between managing risk and enabling innovation, to ensure that businesses are protected without slowing down or blocking important scientific discoveries.  
  • Ask the right questions to assess risk. Our Director of Contracts & Compliance, Andrew Gutierrez, highlighted the need to ask the right questions in developing contracts and programs that will protect a company’s confidentiality and IP.He also talked about the need to verify how your data is being protected by your partners to ensure compliance with global regulations.

The Science Exchange Summit gave our entire team an opportunity to deepen our understanding of the needs of global procurement leaders, and our attendees gained insights to bring back to their own organizations, and a network of experts to collaborate with in the future. I look forward to continuing these discussions with our customers so we can continue to learn from one another and accelerate scientific discovery!

Learn more about how Science Exchange can help you — request a demo today.

New on Science Exchange: ActiveMotif, Optopatch, & CV Tox for World Heart Day

September 20, 2017 | Posted by Team in Drug Discovery, New Innovations, Research |

by Chandreyee Das, Ph.D., Senior Content Manager, Science Exchange | www.scienceexchange.com

We observe World Heart Day at Science Exchange by highlighting a novel technology for assessing cardiac safety, from the Efimov Lab at George Washington University. Other newcomers on our platform that we present to you are ActiveMotif, Oncodesign, QurAlis, and Worldwide Clinical Trials.

ActiveMotif: Time to RIME (Rapid IP-MS of endogenous proteins)

It’s the 20th anniversary of the discovery of chromatin — and researchers can treat their favorite chromatin samples to ActiveMotif’s RIME service (Rapid immunoprecipitation mass spectrometry of endogenous

RIME Method ActiveMotif

RIME service from ActiveMotif includes nuclear isolation, sonication, IP, purification, tryptic digestion, MS, and data analysis

proteins). It is an ideal method for identifying transcriptional cofactors and other associated proteins within multi-protein complexes, and is often performed in parallel with ChIP-seq.

A leading provider of kits and services for studying gene regulation (both genetic and epigenetic), ActiveMotif is no stranger to chromatin. RIME is just one of a comprehensive menu of gene regulation services that ActiveMotif offers through Science Exchange — visit the storefront to browse their capabilities.

 

QurAlis: Harvard team uses Dead Sea microbes in novel assays

Founded in May 2017 by Clifford Woolf, Professor of Neurology and Neurobiology at Harvard Medical School, Kevin Eggan, Professor of Regenerative Biology at Harvard, Kasper Roet, Harvard Research Fellow, and Q-State Biosciences, QurAlis focuses the power of Q-State’s powerful, 100% optical electrophysiology platform on novel, stem cell-derived, disease-in-dish models of ALS.

It’s a Dead Sea microorganism that is the basis of the enabling Q-State technology. QuasAr proteins, derived from this microbe, respond to action potentials and synaptic signals by emitting near-infrared fluorescence. These Optopatch assays thus deliver higher throughput and information content than traditional patch clamp assays, and they also provide better resolution and lower phototoxicity than other optical screening tools.

We’re very excited to have QurAlis join Q-State Biosciences on our network, giving neurobiology researchers easy access to the expertise of the QurAlis team.

 

Worldwide Clinical Trials: Early phase services now available on Science Exchange

In the high-stakes service category of clinical trials, Worldwide stands out. In fact, Worldwide’s Chief Medical and Scientific Officer, Michael F. Murphy, M.D., Ph.D., was recently named one of the PharmaVOICE 100 Most Inspiring People of 2017 — for the impact of Dr. Murphy’s dedication to innovation.

Continuously working to improve trial design and patient outcomes, Worldwide now offers early phase services on the Science Exchange network. Click on the Worldwide storefront to access this major global CRO without needing a separate contract.

 

Efimov Lab: Predictive preclinical models of cardiovascular toxicology

An apt addition to the Science Exchange platform, in time for World Heart Day (September 29!), is the Efimov Laboratory at George Washington University.

Known around the world as a leader in cardiovascular science and biomedical engineering, Dr. Igor Efimov and his team developed a method for optically mapping organotypic cultures of donor human heart slices, enabling users to test the cardiac safety and efficacy of therapeutic candidates.

The culture method preserves heart tissue architecture and extracellular matrix — aspects of heart health that cannot be revealed by iPSC-derived cardiac cells or other traditional assays for cardiovascular toxicology. Visit the lab’s storefront for a list of their recent exciting publications — this is clearly a team to watch.

 

Oncodesign: Preclinical assessment of anti-cancer therapies

True thought leaders in the field of preclinical drug discovery and development, Oncodesign made the news last year when it partnered with Bristol-Myers Squibb to develop novel macrocyclic candidates and test them using their proprietary xenograft models and imaging technology.

Now, Oncodesign’s services are easily accessible to Science Exchange requesters. We get extremely excited thinking that a requester on our platform with a promising therapeutic candidate may now use Oncodesign’s Predict®, Chi-mice®, Pharmimage® and other platforms to characterize their candidate, speeding it along the path to potential cancer patients. Start a conversation with this leading CRO by submitting your Scope of Work here.

 

 

Connect with a new provider today!

Are you new to Science Exchange? See how it works.

The Robotic Cloud Laboratory for the Life Sciences: Transcriptic

September 20, 2017 | Posted by Team in Drug Discovery, Lab Profiles, New Innovations, Research |

Transcriptic LogoBy Natalie Foote, Director of Service Provider Operations, Science Exchange | www.scienceexchange.com

 

In this Provider Innovation Profile, we’re proud to feature Transcriptic, whose automated cellular and molecular biology platform enables scalable life science research with flexibility and precision.

Automation is a rapidly advancing area of biotechnology, and Science Exchange hopes to give our researchers access to unique robotics platforms while helping them save on equipment costs and manage laboratory space limitations.

Transcriptic’s robotic cloud lab paradigm means biologists can be running experiments on the other side of the planet from their lab, leveraging a bank of robotic workcells for massive experimentation.

Transcriptic frees researchers to focus on the creative aspects of their science by providing faster, more reliable and repeatable processes with vastly lower capital costs than previously possible.

Differentiators: Transparency, flexibility, multiplex-ity

Transcriptic Robotic Workcell

Multiple integrated automated devices per workcell

  • Transparency: No other service provider on the planet can tell you exactly how they run an experiment on the user’s behalf. Transcriptic provides deep transparency into how users’ experiments were run by executing experiments exactly as specified and also providing retrospective diagnostic data on individual instrument performance during the experiment.
  • Flexible robotics: Being a robotic cloud lab, the Transcriptic system can dynamically provision robotic resources to process samples for users. For example, the system might start the week at a scale of one plate and end the week on hundreds of plates. Users only pay for the resources they use, reaping the reproducibility and throughput benefits of robotics without any of the overhead.
  • Easy multiplexing: The Transcriptic web application makes it easy as checking a box to detect an additional analyte in your sample. When it’s that easy, you can perform multiplexed quantiation of more analytes, starting to generate a more accurate picture of the phenotypic state of your sample.

Featured Service: Mesocale Discovery (MSD) Assay

The MSD assay, validated in many bioanalytical methods per U.S. FDA and EMA guidances, is offered as a service by Transcriptic. The Mesoscale Discovery Sector S 600 instrument is fully integrated with the Transcriptic robotic cloud lab.

The MSD S 600 instrument performs multiplexed detection of up to 10 analytes per well, ensuring the highest data-to-sample quantity efficiency, in immunoassays. Multiple assay panels are available from the V-Plex line, all conducted with complete automated precision by robots in the cloud. Custom panel assays are also available through the MSD U-Plex system.

Why requesters choose Transcriptic

Transcriptic, in collaboration with multiple biopharma companies and non-academic laboratories, has delivered many peer-reviewed publications and conference presentations.

Transcriptic presented one interesting study at SynBioBeta 2016. In collaboration with EpiBiome, Transcriptic’s automated platform provided a robust, reproducible and high-throughput method for on-demand microbiome characterization. This workflow captured sample prep through NGS and sequencing analysis in 7-10 days, allowing for fast, iterative cycles of microbiome screening.

Visit the Transcriptic storefront today to request some quotes!

 

New on Science Exchange: Nobel-worthy Nanosensors, MacroDSF, Fluidigm, and More

August 22, 2017 | Posted by Team in Drug Discovery, Lab Profiles, New Innovations, Research |

Nobel-worthy nanosensors

In 2007, Charles Lieber, the Harvard scientist who many say is in the running for a Nobel prize, co-founded Vista NanoBioSciences to enable drug discovery researchers to use his team’s nanosensor technologies for label-free, ultrasensitive detection of proteins, nucleic acids, and even single viral particles.

Functionalized Nanowires Vista NanoBioSciences

Vista NanoBioSciences’ ultrasensitive biomarker detection platform (left) uses functionalized nanowires (“NW”) that respond to interactions with individual biomolecules.

Vista NanoBioSensor

Now available through Science Exchange, Vista NanoBioSciences offers biomarker assays using its portable NanoBioSensor™ and BioTracker™ platforms. Vista’s NanoBioSensor precisely detects and measures biomarkers in a finger-stick drop of blood, other bodily fluid, or tissue culture – without labeling and in less than 10 minutes. Vista’s BioTracker provides continuous monitoring of dynamic changes in the targeted analytes of any biological material.  Both devices are portable, exhibiting very high sensitivity (10³ increase over ELISA), high specificity, across multiple logs of concentration, in real time.

Taking the pain out of protein purification with MacroDSF

Empowered by high-throughput protein purification and structure determination technologies, structure-based drug discovery is enjoying a resurgence.

NovAliX, a new provider on the Science Exchange network, gives you access to the ProteoPlex MacroDSF platform, an exciting tool for rapidly optimizing conditions for protein purification and crystallization.

The instrument quickly optimizes  protein concentration, pH value, salt, buffer, stabilizing additive, etc — potentially increasing a purified protein’s stability or even the resolution of its crystal structure!

NovAliX also offers a broad range of biophysical characterization services to provide a complete picture of the protein of interest.

Fluidigm custom assay development

Interested in Fluidigm’s powerful mass cytometry and microfluidics platforms, but lack the resources to design the perfect assay?

Now you can take advantage of Fluidigm’s expertise using the company’s own team of assay development scientists. Through Science Exchange, you can order custom assays for Fluidigm’s CyTOF®, Helios®, and integrated fluidic circuit-based platforms.

Oncology, from ABL1 to ZAP70

Based in Freiburg, Germany, ProQinase has been supporting oncology research for 16 years. Now on Science Exchange, ProQinase offers biochemical assay services (such as kinase screens), cellular assay services (such as proliferation, invasion and spheroid assays), and in vivo assay services (including immuno-oncology and metastasis models).

The scientific staff at ProQinase are thought leaders in oncology research. At the 2017 AACR Annual Meeting, they presented a novel assay platform to distinguish ATP-competitive from non-ATP-competitive kinase inhibitors.

Medicinal chemistry and process optimization

If you’re looking for a full-service laboratory to execute your chemistry projects, you’ll be happy to see the addition of Kalexsyn, a chemical synthesis powerhouse based in Michigan, U.S.A, to the Science Exchange network.

Whether it’s developing novel scaffolds, SAR, modification of complex natural products or challenging macrocyclic peptides, Kalexsyn’s deep bench of Ph.D. chemists provides IP-enabling expertise.

The Kalexsyn team has produced over 1000 publications and patents and has served over 85 pharmaceutical and biotechnology companies.

 

Connect with a new provider today!

Are you new to Science Exchange? See how it works.

In vivo Phenotypic Screening: Melior Discovery

August 19, 2017 | Posted by Team in Drug Discovery, Helpful products, Lab Profiles, New Innovations, Research |

By Natalie Foote, Director of Service Provider Operations, Science Exchange | www.scienceexchange.com

Melior Logo

Phenotypic Screening Pioneer Launches Novel Analgesia Panel

In this Provider Innovation Profile, we’re proud to feature Melior Discovery, a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning.

Melior’s platform evaluates compounds through up to 40 different animal models representing 14 broad therapeutic areas, potentially uncovering therapeutic efficacy that might be undetected using traditional assessments.

Recently, Melior made the news with its novel opioidTRACE® Analgesic Profiling Platform. Given the need to develop low-abuse analgesics to address the opioid crisis, Melior has configured an in vivo platform aimed at specifically profiling opioid therapeutics and related analgesics.

The opioidTRACE® platform addresses the multiple features characteristic of opioids, including rodent models that evaluate acute analgesia, chronic analgesia, respiratory depression, GI mobility, and abuse liability. In addition to opioid testing, Melior has a wide array of animal models of analgesia ranging models of acute pain to chronic neuropathy models. 

[click to view larger view of opioidTRACE® animal models]Opioid Trace In Vivo Models

Backed by Expertise in In Vivo Screening

Melior’s new panel is just the latest demonstration of the team’s unique know-how in applying “production-mode” methods for in vivo screening across multiple therapeutic areas. Its proprietary theraTRACE® platform enables rapid and cost-effective identification of new therapeutic potential by systematically screening candidates in a diverse array of validated in vivo disease models.

Fibrosis is another disease area for which Melior’s panels have exemplified the utility of in vivo  phenotypic screening. Melior has validated models of liver and lung fibrosis; download the validation data for these models from the Resources section of Melior’s Science Exchange storefront.

Why Requesters are Choosing Melior for In vivo Studies

Melior’s capability directly translates to efficiencies combined with high levels of quality for their clients. Positive ratings and testimonials illustrate the benefits that attract repeat business for Melior:

  • High reproducibility and predictive power of in vivo methodologies, models, and assays assuring high quality of data
  • Lower overall costs resulting from the availability of highly cost effective preclinical services from Melior
  • Rapid responses to requests for service and quick turnaround times for preclinical studies
  • Ability to rapidly customize, design, and modify models in response to requests for specialized in vivo services or changes in protocols or unexpected results at any stage of the study

Dr. Sridharan Rajamani, Senior Research Scientist at Gilead Sciences, said that his team chose Melior Discovery because they were responsive and cost effective.  “We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail,” said Dr. Rajamani. “Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.”  

Interested in working with Melior Discovery? Request a quote to start the discussion.

New Service Providers Available on Science Exchange

August 2, 2017 | Posted by Team in Drug Discovery, Lab Profiles, New Innovations, Research |
Image of Colon Tumor Cells courtesy of OcellO

Image of Colon Tumor Stem Cells courtesy of OcellO

If you aren’t exploring the latest cell culture models of human tissue for nonclinical and preclinical testing, you should be.

That’s the bottom line of today’s Science Exchange service provider roundup — three of the five newest service providers on our platform are experts in developing predictive models.

Advances in predictive model systems

Axiogenesis, based in Germany, develops iPSC-derived models of cardiac tissue, neurons, and other cell types. In late 2016, the company made the news when researchers at the United States FDA published a peer-reviewed study showing that Axiogenesis’s Cor.4U cardiomyocyte model was the most predictive model in cardiac safety tests. Last month, researchers at Wake Forest University used the Cor.4U model to develop a digitally trackable beating-heart biosensor. The future of cardiac safety clearly lies beyond hERG channel electrophysiology!

Generating tissue models with precise spatial resolution is possible using 3D bioprinting, in which Cypre Biotech is an expert. Based in San Francisco, USA, the company focuses on customizing the extracellular matrix of tumor microenvironment models to match certain cancer subtypes. Given the impact of new cancer drugs, including certain immunotherapies, on the tumor microenvironment, technologies such as that developed by Cypre are going to be needed for testing safety and efficacy.

The third service provider in this roundup excelling in the development of clinically relevant microtissue models is OcellO, headquartered in the Netherlands. Researchers at OcellO have published numerous peer-reviewed studies showing how combining three-dimensional tissue culture with high-throughput imaging can enable efficient, automated screening and phenotypic profiling. Their most recent publication showed that phenotypic screening of kinase inhibitors could reveal potential new targets for polycystic kidney disease (view abstract in the Resources section of the OcellO storefront).

Analytical methods for translational research

As model systems advance in complexity and throughput, analytical methods must keep pace. Two service providers new on Science Exchange are known for their expertise in developing reliable analytical methods.

Pangaea Oncology is one of the most prestigious laboratories in the world in the fields of molecular diagnostics, pathology, and related analysis services for translational research. We are thrilled to have the Pangaea team, led by expert Dr. Rafael Rosell and Nobel laureate Dr. Santiago Ramón y Cajal, join the Science Exchange platform! Pangaea Oncology was the first laboratory in Spain to be accredited to perform certain genetic tests for cancer in serum/plasma samples, advancing precision medicine.

We also bring you Metis Laboratories, whose analytical expertise centers on radiotracer-based assays. These assays remain one of the most sensitive and specific platforms for assessing ligand binding and compound distribution; however, complex handling requirements mean that outsourcing these studies is far more practical than developing radiotracer assays in house.

Connect with a new provider today!

Are you new to Science Exchange? See how it works.

Covance Nonclinical Services Now Listed On Science Exchange

June 14, 2017 | Posted by Team in Company, Drug Discovery, Science Exchange News, Uncategorized |

Covance   +  Science Exchange

 

Biopharma scientists seeking to outsource nonclinical studies have a new way to access the scientific expertise of Covance, a market leader in drug development. Covance’s nonclinical scientific services – including lead optimization, safety assessment, drug metabolism and bioanalytical solutions – are now available through Science Exchange. Scientists can order available study services from Covance by visiting the Covance Storefront on ScienceExchange.com. Or they can contact the Science Exchange Concierge Service to have a Sourcing Manager prepare custom quotes and provide start-to-finish project management.

Scientists from around the world already use Science Exchange to save time and money by ordering services from our network of more than 6400 pre-qualified service providers. With Covance joining the Science Exchange network, scientists can further benefit by being able to easily access the deep nonclinical scientific expertise of one of the world’s top CROs through the convenience of the Science Exchange platform. 

In addition, researchers at companies who have established enterprise-level Master Service Agreements (MSAs) with Science Exchange can get projects started with Covance almost instantly.

As an introductory offer, through September 30, 2017, requesters can take advantage of special fast study starts on select GLP Toxicology in vivo studies or full IND/CTA-enabling packages available from Covance, ordered through the Science Exchange platform.  

Request a quote today — access nonclinical scientific services from Covance through the Covance Storefront on Science Exchange.

 

* To be eligible for introductory offer, work must begin by September 30, 2017. Additional terms and conditions apply.  This is a limited time, limited capacity offer – Covance reserves the right to end these promotions at any time, without notice.

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com